West Pharmaceutical [WST] vs Intuitive Surgical [ISRG] Detailed Stock Comparison
West Pharmaceutical
NYSE
Loading...
Intuitive Surgical
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: West Pharmaceutical wins in 10 metrics, Intuitive Surgical wins in 9 metrics, with 0 ties. West Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | West Pharmaceutical | Intuitive Surgical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 40.74 | 63.00 | West Pharmaceutical |
| Price-to-Book Ratio | 6.69 | 9.08 | West Pharmaceutical |
| Debt-to-Equity Ratio | 10.52 | 0.00 | Intuitive Surgical |
| PEG Ratio | 2.06 | 2.59 | West Pharmaceutical |
| EV/EBITDA | 24.57 | 49.26 | West Pharmaceutical |
| Profit Margin (TTM) | 16.48% | 28.51% | Intuitive Surgical |
| Operating Margin (TTM) | 20.87% | 30.47% | Intuitive Surgical |
| EBITDA Margin (TTM) | 20.87% | 30.47% | Intuitive Surgical |
| Return on Equity | 17.72% | 16.04% | West Pharmaceutical |
| Return on Assets (TTM) | 10.53% | 9.02% | West Pharmaceutical |
| Free Cash Flow (TTM) | $276.40M | $1.30B | Intuitive Surgical |
| Dividend Yield | 0.38% | N/A | N/A |
| 1-Year Return | -9.10% | -7.24% | Intuitive Surgical |
| Price-to-Sales Ratio (TTM) | 6.62 | 17.73 | West Pharmaceutical |
| Enterprise Value | $19.40B | $156.94B | Intuitive Surgical |
| EV/Revenue Ratio | 6.55 | 17.16 | West Pharmaceutical |
| Gross Profit Margin (TTM) | 35.73% | 66.31% | Intuitive Surgical |
| Revenue per Share (TTM) | $41 | $26 | West Pharmaceutical |
| Earnings per Share (Diluted) | $6.69 | $7.18 | Intuitive Surgical |
| Beta (Stock Volatility) | 1.07 | 1.61 | West Pharmaceutical |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
West Pharmaceutical vs Intuitive Surgical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| West Pharmaceutical | -1.65% | 2.98% | 5.89% | 21.04% | 33.06% | -18.37% |
| Intuitive Surgical | -0.59% | 2.38% | -4.32% | -15.90% | -3.00% | -14.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| West Pharmaceutical | -9.10% | 8.30% | -8.21% | 375.72% | 1,389.28% | 1,825.79% |
| Intuitive Surgical | -7.24% | 145.65% | 79.24% | 765.95% | 1,346.41% | 5,952.36% |
News Based Sentiment: West Pharmaceutical vs Intuitive Surgical
West Pharmaceutical
News based Sentiment: POSITIVE
West Pharmaceutical Services reported a strong Q2, exceeding expectations and reaffirming guidance, which fueled analyst optimism and increased price targets. While valuation remains a concern and operational challenges exist, the overall narrative is positive, suggesting continued growth potential and making it a compelling investment option.
Intuitive Surgical
News based Sentiment: POSITIVE
Intuitive Surgical demonstrated strong financial performance in Q2 2025, coupled with significant product innovation and regulatory approvals. While analyst price targets were mixed, the overall sentiment remains positive, supported by a 'Moderate Buy' consensus and increased institutional holdings, suggesting continued growth potential.
Performance & Financial Health Analysis: West Pharmaceutical vs Intuitive Surgical
| Metric | WST | ISRG |
|---|---|---|
| Market Information | ||
| Market Cap | $19.60B | $163.30B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 658,600 | 2,417,000 |
| 90 Day Avg. Volume | 619,057 | 2,455,233 |
| Last Close | $268.07 | $449.69 |
| 52 Week Range | $187.43 - $352.33 | $425.00 - $616.00 |
| % from 52W High | -23.92% | -27.00% |
| All-Time High | $475.35 (Sep 06, 2021) | $616.00 (Jan 20, 2025) |
| % from All-Time High | -43.61% | -27.00% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.21% |
| Quarterly Earnings Growth | 0.18% | 0.25% |
| Financial Health | ||
| Profit Margin (TTM) | 0.16% | 0.29% |
| Operating Margin (TTM) | 0.21% | 0.30% |
| Return on Equity (TTM) | 0.18% | 0.16% |
| Debt to Equity (MRQ) | 10.52 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $40.74 | $49.79 |
| Cash per Share (MRQ) | $7.09 | $14.86 |
| Operating Cash Flow (TTM) | $676.70M | $2.83B |
| Levered Free Cash Flow (TTM) | $207.85M | $1.82B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.38% | N/A |
| Last 12-Month Dividend | $0.83 | N/A |
Valuation & Enterprise Metrics Analysis: West Pharmaceutical vs Intuitive Surgical
| Metric | WST | ISRG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 40.74 | 63.00 |
| Forward P/E | 36.24 | 57.55 |
| PEG Ratio | 2.06 | 2.59 |
| Price to Sales (TTM) | 6.62 | 17.73 |
| Price to Book (MRQ) | 6.69 | 9.08 |
| Market Capitalization | ||
| Market Capitalization | $19.60B | $163.30B |
| Enterprise Value | $19.40B | $156.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.55 | 17.16 |
| Enterprise to EBITDA | 24.57 | 49.26 |
| Risk & Other Metrics | ||
| Beta | 1.07 | 1.61 |
| Book Value per Share (MRQ) | $40.74 | $49.79 |
Financial Statements Comparison: West Pharmaceutical vs Intuitive Surgical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | WST | ISRG |
|---|---|---|
| Revenue/Sales | $766.50M | $2.44B |
| Cost of Goods Sold | $492.60M | $822.10M |
| Gross Profit | $273.90M | $1.62B |
| Research & Development | $19.10M | $313.30M |
| Operating Income (EBIT) | $158.90M | $743.40M |
| EBITDA | $203.40M | $898.70M |
| Pre-Tax Income | $157.00M | $832.10M |
| Income Tax | $30.20M | $167.90M |
| Net Income (Profit) | $131.80M | $664.20M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | WST | ISRG |
|---|---|---|
| Cash & Equivalents | $509.70M | $2.57B |
| Total Current Assets | $1.68B | $7.66B |
| Total Current Liabilities | $604.60M | $1.54B |
| Long-Term Debt | $282.40M | N/A |
| Total Shareholders Equity | $2.93B | $17.21B |
| Retained Earnings | $4.14B | $7.14B |
| Property, Plant & Equipment | $3.28B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | WST | ISRG |
|---|---|---|
| Operating Cash Flow | $177.40M | $833.10M |
| Capital Expenditures | N/A | $-116.60M |
| Free Cash Flow | $101.90M | $465.00M |
| Debt Repayment | $-300,000 | N/A |
| Common Stock Repurchase | $-500,000 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | WST | ISRG |
|---|---|---|
| Shares Short | 1.68M | 5.72M |
| Short Ratio | 2.92 | 2.50 |
| Short % of Float | 0.03% | 0.02% |
| Average Daily Volume (10 Day) | 658,600 | 2,417,000 |
| Average Daily Volume (90 Day) | 619,057 | 2,455,233 |
| Shares Outstanding | 72.30M | 356.60M |
| Float Shares | 71.41M | 356.30M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.98% | 0.89% |
Dividend Analysis & Yield Comparison: West Pharmaceutical vs Intuitive Surgical
| Metric | WST | ISRG |
|---|---|---|
| Last 12-Month Dividend | $0.83 | N/A |
| Last 12-Month Dividend Yield | 0.38% | N/A |
| 3-Year Avg Annual Dividend | $0.79 | N/A |
| 3-Year Avg Dividend Yield | 0.07% | N/A |
| 3-Year Total Dividends | $2.37 | N/A |
| Ex-Dividend Date | Apr 30, 2025 | N/A |